Merck faces a looming challenge with the 2028 patent expiration of Keytruda, but it’s not sitting around twiddling test tubes ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at ...

Merck & Co., Inc. (NYSE:MRK) is another biopharmaceutical company on the list of the 10 undervalued blue chip stocks analysts ...

The FDA’s upcoming June meeting plans to jab at a lineup of vaccines—COVID-19, RSV, flu, and even anthrax—but somehow skipped ...

A few of the new members Health Secretary Robert F. Kennedy Jr. appointed to the federal panel have promoted misinformation ...

Merck’s MRK second-largest product is Gardasil, which is a vaccine for the prevention of certain cancers caused by human ...

Merck & Co., Inc. (NYSE:MRK) is one of the 15 best stocks to invest in for an 18 year old. On June 10, Cantor Fitzgerald ...

One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy Jr. has earned thousands of dollars as an ...

Merck’s shares have fallen nearly 40% over the past 12 months, driven by uncertainty around the future of Gardasil, which protects against cancer-causing HPV infections, and mounting concerns ...

A federal judge ruled in Merck & Co.’s favor in a safety lawsuit over its Gardasil vaccine, allowing the drugmaker to sidestep more than 200 cases claiming the company concealed safety risks.